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Following the introduction of transcatheter aortic valve im-
plantation (TAVI), it is now possible to treat elderly patients
with severe aortic stenosis and a high surgical risk. This
advancement in interventional cardiology has led to increased
survival, health status and quality of life. However, as with
many invasive interventional procedures, TAVI is associated
with the risk of cerebral embolisation and consequent ischae-
mic cerebrovascular events with possible neurological impair-
ment. The risk estimates of post-procedural stroke associated
with TAVI vary from 1.5 to 10 % and have been reported both
early and late after the procedure. In the PARTNER Cohort B
study, the Canadian multicentre TAVI registry and the study
by Nuis et al., about 50 % of the stroke events occurred more
than 24 h post-procedure [1]. In addition to clinically overt
stroke, asymptomatic silent cerebral infarcts have been fre-
quently observed on MRI, with a prevalence ranging from 62
to 93 % [2]. Although asymptomatic, accumulating evidence
implicates that these silent cerebral infarcts are related to risk
of future stroke, cognitive decline, dementia, and depression.
Whether stroke occurs due to incomplete endothelialisation of
the valve or by new onset of silent atrial fibrillation is un-
known. Early post-procedural stroke (<24 h) is more likely the
result of embolisation during valve implantation.
Given this high incidence of cerebral events, adequate
anticoagulation is probably required both during the proce-
dure and in the followingmonths. However, the exact regimen
of anticoagulation involves a clinical dilemma with the ther-
apeutic potential of reducing ischaemic complications at the
expense of increasing the bleeding risk. The overall incidence
of bleeding following TAVI has been reported in 41 % of the
patients in the meta-analysis conducted by Généreux et al., of
which 16 % were life-threatening [3]. It is important to bear in
mind that life-threatening bleeding is associated with a six- to
nine-fold increase in 30-day mortality after procedure and acts
as an independent predictor of 1-year mortality [4]. Therefore,
for clinical decision-making on antithrombotic treatment, it is
important to find a balance between prevention of ischaemic
complications and avoidance of bleeding risk.
The recently published study by Nijenhuis et al. addresses
this clinical dilemma regarding decision-making on
anticoagulation treatment of elderly patients treated with TAVI
[5]. As pointed out by the authors, the current European and
American guidelines merely provide recommendations based
on retrospective registries. The European Society of Cardiol-
ogy guidelines recommend a combination of low aspirin and a
thienopyridine early after TAVI, followed by aspirin or a
thienopyridine alone. In those cases where there is an indica-
tion for treatment with vitamin K antagonists, such as in atrial
fibrillation, a combined treatment of vitamin K antagonist and
aspirin or a thienopyridine is in general installed. However,
the guidelines do not provide any recommendations on the
duration of dual antiplatelet therapy (DAPT).
As observed in the survey undertaken in the Netherlands, a
wide heterogeneity in the duration of dual antiplatelet therapy
(DAPT) and loading dose of clopidogrel was noted. In two-
thirds of the centres (n=9) DAPTwas prescribed for 3 months.
In one centre, where only transapical TAVI is performed, no
concomitant clopidogrel was prescribed at all. The duration of
concomitant clopidogrel was dependent on the type of pros-
thesis in only two centres according to the recommendations
of the respective manufactures, 6 months versus 3 months for
supra-annular Core Valve™ and intra-annular prostheses (e.g.
SAPIEN™, JenaValve), respectively. Whether the decision on
the duration of concomitant clopidogrel and its loading dose
indeed should be dependent on the valve type (SAPIEN™ or
Medtronic Core Valve™) or procedural approach
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(transfemoral or apical) has not been described in the litera-
ture. Moreover, clinical decision-making becomes more com-
plex in circumstances where there is a high bleeding risk, PCI
(<1 year) prior to TAVI, triple therapy pre-TAVI and new-
onset atrial fibrillation. This is nicely illustrated in the survey
of the participating centres showing different approaches to
these scenarios.
In conclusion, the appropriate regimen of antiplatelet and
anticoagulant therapy following TAVI is undefined and war-
rants the conduction of randomised controlled trials for clinical
decision-making in this steadily growing patient population.
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